|
| 34887529 | Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers. | Neuropsychopharmacology | 2022 |
| 35992305 | Identification of potent inhibitors of SARS-CoV-2 infection by combined pharmacological evaluation and cellular network prioritization. | iScience | 2022 |
| 35929015 | A review of clinical efficacy data supporting emergency use authorization for COVID-19 therapeutics and lessons for future pandemics. | Clin Transl Sci | 2022 |
| 36385931 | Advancing New Chemical Modalities into Clinical Studies. | ACS Med Chem Lett | 2022 |
| 36345421 | In vivo Characterization of the Opioid Receptor-Binding Profiles of Samidorphan and Naltrexone in Rats: Comparisons at Clinically Relevant Concentrations. | Neuropsychiatr Dis Treat | 2022 |
| 33907750 | Identification of druggable host targets needed for SARS-CoV-2 infection by combined pharmacological evaluation and cellular network directed prioritization both in vitro and in vivo. | bioRxiv | 2022 |
| 33417425 | Early Returns on Small Molecule Therapeutics for SARS-CoV-2. | ACS Infect Dis | 2021 |
| 34437808 | Recognition of Divergent Viral Substrates by the SARS-CoV-2 Main Protease. | ACS Infect Dis | 2021 |
| 33426509 | A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual screening. | iScience | 2021 |
| 33200116 | A Multi-Pronged Approach Targeting SARS-CoV-2 Proteins Using Ultra-Large Virtual Screening. | ChemRxiv | 2020 |
| 31294646 | Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates. | J Psychopharmacol | 2019 |
| 31850398 | An open toolkit for tracking open science partnership implementation and impact. | Gates Open Res | 2019 |
| 30108159 | In Vitro Pharmacological Characterization of Buprenorphine, Samidorphan, and Combinations Being Developed as an Adjunctive Treatment of Major Depressive Disorder. | J Pharmacol Exp Ther | 2018 |
| 28939558 | Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib). | Mol Cancer Ther | 2017 |
| 26230873 | Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases. | J Med Chem | 2015 |
| 26524333 | Delivery of long-acting injectable antivirals: best approaches and recent advances. | Curr Opin Infect Dis | 2015 |
| 24900811 | Discovery of Thienoimidazole-Based HCV NS5A Genotype 1a and 1b Inhibitors. | ACS Med Chem Lett | 2013 |
| 22221201 | VX-322: a novel dual receptor tyrosine kinase inhibitor for the treatment of acute myelogenous leukemia. | J Med Chem | 2012 |
| 21970471 | Design, synthesis, and evaluation of a novel dual FMS-like tyrosine kinase 3/stem cell factor receptor (FLT3/c-KIT) inhibitor for the treatment of acute myelogenous leukemia. | J Med Chem | 2011 |
| 19827834 | Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control. | J Med Chem | 2009 |
| 19894743 | In vitro and in vivo isotope effects with hepatitis C protease inhibitors: enhanced plasma exposure of deuterated telaprevir versus telaprevir in rats. | J Med Chem | 2009 |
| 20014869 | Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindole. | J Med Chem | 2009 |
| 17289835 | (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. | J Pharmacol Exp Ther | 2007 |
| 17300186 | Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors. | J Med Chem | 2007 |
| 16306447 | c-Jun N-terminal kinases mediate reactivation of Akt and cardiomyocyte survival after hypoxic injury in vitro and in vivo. | Circ Res | 2006 |
| 15023894 | Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease. | Circulation | 2004 |
| 12669025 | Designing screens: how to make your hits a hit. | Nat Rev Drug Discov | 2003 |
| 8999827 | Phosphorylation of serine residues 3, 6, 10, and 13 distinguishes membrane anchored from soluble glutamic acid decarboxylase 65 and is restricted to glutamic acid decarboxylase 65alpha. | J Biol Chem | 1997 |
| 7578060 | Substrate-induced inactivation of a crippled beta-glucosidase mutant: identification of the labeled amino acid and mutagenic analysis of its role. | Biochemistry | 1995 |
| 8519777 | Mechanism of Agrobacterium beta-glucosidase: kinetic analysis of the role of noncovalent enzyme/substrate interactions. | Biochemistry | 1995 |
| 7519242 | Higher autoantibody levels and recognition of a linear NH2-terminal epitope in the autoantigen GAD65, distinguish stiff-man syndrome from insulin-dependent diabetes mellitus. | J Exp Med | 1994 |
| 8252556 | Syntheses of 2-deoxy-2-fluoro mono- and oligo-saccharide glycosides from glycals and evaluation as glycosidase inhibitors. | Carbohydr Res | 1993 |
| 1304351 | Design, synthesis, and characterization of a protein sequencing reagent yielding amino acid derivatives with enhanced detectability by mass spectrometry. | Protein Sci | 1992 |
| 1964382 | Synthesis and anticonvulsant activity of 3-alkoxycarbonylaminomethylcarbonylamino-4-benzoylpyridines . | Drug Des Deliv | 1990 |